Kodiak Sciences to Participate in Upcoming Investor Conferences
Kodiak Sciences (Nasdaq: KOD), a biopharmaceutical company focused on retinal disease therapeutics, announced its participation in upcoming investor conferences.
Management will present at the Jefferies London Healthcare Conference on November 21, 2024, at 9:00 AM GMT in London, UK, and at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 2:35 PM ET in Coral Gables, Florida.
Live webcasts of the presentations will be available on the
Kodiak Sciences (Nasdaq: KOD), una compagnia biofarmaceutica focalizzata sulle terapie per le malattie retiniche, ha annunciato la sua partecipazione a prossimi convegni per investitori.
La direzione presenterà alla Jefferies London Healthcare Conference il 21 novembre 2024, alle 9:00 GMT a Londra, Regno Unito, e alla 7a Annual Evercore ISI HealthCONx Conference il 3 dicembre 2024, alle 14:35 ET a Coral Gables, Florida.
Le dirette delle presentazioni saranno disponibili sul sito web.
Kodiak Sciences (Nasdaq: KOD), una empresa biofarmacéutica centrada en terapias para enfermedades retinianas, anunció su participación en próximas conferencias de inversores.
La dirección presentará en la Jefferies London Healthcare Conference el 21 de noviembre de 2024, a las 9:00 AM GMT en Londres, Reino Unido, y en la 7ª Conferencia Anual Evercore ISI HealthCONx el 3 de diciembre de 2024, a las 2:35 PM ET en Coral Gables, Florida.
Las transmisiones en vivo de las presentaciones estarán disponibles en el sitio web.
코디악 사이언스 (Nasdaq: KOD)는 망막 질환 치료에 초점을 맞춘 생명공학 기업으로, 다가오는 투자자 회의에 참석할 것이라고 발표했습니다.
경영진은 2024년 11월 21일 오전 9시 GMT에 영국 런던에서 열리는 제프리 런던 헬스케어 컨퍼런스와 2024년 12월 3일 오후 2시 35분 ET에 플로리다주 코랄 게이블스에서 열리는 제7회 에버코어 ISI 헬스CONx 회의에서 발표할 예정입니다.
발표에 대한 실시간 웹캐스트는 웹사이트에서 이용할 수 있습니다.
Kodiak Sciences (Nasdaq: KOD), une société biopharmaceutique axée sur les traitements des maladies rétiniennes, a annoncé sa participation à des conférences pour investisseurs à venir.
La direction fera une présentation lors de la Jefferies London Healthcare Conference le 21 novembre 2024, à 9h00 GMT à Londres, Royaume-Uni, et lors de la 7e Conférence Annuelle Evercore ISI HealthCONx le 3 décembre 2024, à 14h35 ET à Coral Gables, Floride.
Des webdiffusions en direct des présentations seront disponibles sur le site.
Kodiak Sciences (Nasdaq: KOD), ein biopharmazeutisches Unternehmen, das sich auf Therapeutika für Netzhauterkrankungen konzentriert, hat seine Teilnahme an bevorstehenden Investorenkonferenzen bekannt gegeben.
Das Management wird am 21. November 2024 um 9:00 GMT auf der Jefferies London Healthcare Conference in London, Großbritannien, und am 3. Dezember 2024 um 14:35 ET auf der 7. jährlichen Evercore ISI HealthCONx Conference in Coral Gables, Florida, präsentieren.
Live-Webcasts der Präsentationen werden auf der Website verfügbar sein.
- None.
- None.
- Jefferies London Healthcare Conference, November 21, 2024, 9:00 AM GMT (1:00 AM PT),
London, UK - 7th Annual Evercore ISI HealthCONx Conference, December 3, 2024, 2:35 PM ET (11:35 AM PT),
Coral Gables, Florida
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABCD Platform™ uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine. We are developing a portfolio of three clinical programs, two of which are late-stage today and derived from our ABCD Platform and one which is platform-independent and which we believe can progress rapidly into pivotal studies.
Kodiak's lead investigational medicine, tarcocimab, is a novel anti-VEGF antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 clinical trials, GLOW2 in patients with diabetic retinopathy and DAYBREAK in patients with wet AMD. Both studies are actively enrolling patients.
KSI-501 is our second investigational medicine, a first-in-class anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate designed to inhibit both IL-6 mediated inflammation and VEGF-mediated angiogenesis and vascular permeability. KSI-501 is being developed for the treatment of high prevalence retinal vascular diseases to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. The Phase 3 DAYBREAK study of KSI-501 in wet AMD is actively enrolling patients.
KSI-101, our third product candidate, is a novel anti-IL-6, VEGF-trap bispecific protein. Kodiak is developing KSI-101 for the treatment of retinal inflammatory diseases, as currently there are no available intravitreal biologic therapies addressing the spectrum of inflammatory conditions of the retina. The Phase 1b APEX study of KSI-101 is actively enrolling patients, as a precursor to activating the Phase 2b/3 PEAK and PINNACLE studies in patients with macular edema secondary to inflammation (MESI).
Kodiak is advancing its Antibody Biopolymer Conjugate Drug (ABCD) Platform that embeds small molecules and other active pharmaceutical ingredients ("APIs") into Kodiak's proprietary biopolymer backbone to enable high drug-antibody-ratio ("DAR") medicines. The diverse APIs are designed to be released over time to achieve targeted, multi-specific and tailored modulation of biological pathways. The unique combination of high DAR and tailored therapeutic benefit offers potential for broad application to multifactorial diseases and builds directly from our Antibody Biopolymer Conjugate technology and its 15 years of design, development and manufacturing experience.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-participate-in-upcoming-investor-conferences-302300603.html
SOURCE Kodiak Sciences Inc.
